2022
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. Npj Breast Cancer 2022, 8: 119. PMID: 36344517, PMCID: PMC9640562, DOI: 10.1038/s41523-022-00492-0.Peer-Reviewed Original ResearchBreast cancerYounger patientsHER2-negative breast cancerNode-positive breast cancerNode-negative diseaseSame clinical featuresHigh mutation burdenLower mRNA expressionAdjuvant chemotherapyMicroarray cohortTAILORx trialOvarian suppressionOlder patientsPatient ageClinical featuresProliferation-related gene expressionScore 0Mutation burdenCopy number gainsOlder womenGATA3 mutationsAge groupsGene signatureMRNA expressionChemotherapy
2009
Triple-negative breast cancer—current status and future directions
Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer—current status and future directions. Annals Of Oncology 2009, 20: 1913-1927. PMID: 19901010, DOI: 10.1093/annonc/mdp492.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBasal-like breast cancerBreast cancerBreast cancer—current statusStandard cytotoxic chemotherapy regimensHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Common cytotoxic agentsCytotoxic chemotherapy regimensGrowth factor receptor 2Factor receptor 2Chemotherapy regimensClinical featuresUnfavorable prognosisProgesterone receptorLack of expressionNovel agentsReceptor 2Cytotoxic agentsPrognosisComplete concordanceCancerGene expression analysisHigh-throughput gene expression analysisRegimens
1999
Relapse after complete response to anthracycline‐based combination chemotherapy in metastatic breast cancer
Pusztai L, Asmar L, Smith T, Hortobagyi G. Relapse after complete response to anthracycline‐based combination chemotherapy in metastatic breast cancer. Breast Cancer Research And Treatment 1999, 55: 1-8. PMID: 10472774, DOI: 10.1023/a:1006161906667.Peer-Reviewed Original ResearchConceptsAnthracycline-based combination chemotherapyComplete clinical responseDisease-free intervalMetastatic breast cancerInitial disease-free intervalSecond relapseFirst relapseCombination chemotherapyCR durationMedian survivalBreast cancerShorter CR durationSite of recurrenceLength of survivalMore frequent recurrenceClinical characteristicsClinical responseFirst recurrenceMetastatic diseaseVisceral sitesComplete responseClinical featuresMetastatic sitesSubsequent therapySecond recurrence